1. Home
  2. GPRO vs VTVT Comparison

GPRO vs VTVT Comparison

Compare GPRO & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoPro Inc.

GPRO

GoPro Inc.

HOLD

Current Price

$0.78

Market Cap

154.6M

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

N/A

Current Price

$31.59

Market Cap

148.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GPRO
VTVT
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.6M
148.7M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
GPRO
VTVT
Price
$0.78
$31.59
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$53.00
AVG Volume (30 Days)
6.9M
31.5K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
79.08
N/A
EPS
N/A
N/A
Revenue
$651,542,000.00
N/A
Revenue This Year
$23.14
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$14.00
52 Week High
$3.05
$44.00

Technical Indicators

Market Signals
Indicator
GPRO
VTVT
Relative Strength Index (RSI) 32.19 43.80
Support Level $0.74 $31.51
Resistance Level $1.88 $33.11
Average True Range (ATR) 0.10 1.89
MACD -0.04 -0.26
Stochastic Oscillator 2.36 17.02

Price Performance

Historical Comparison
GPRO
VTVT

About GPRO GoPro Inc.

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: